Reduced acquisition time PET pharmacokinetic modelling using simultaneous ASL–MRI: proof of concept

TY - JOUR

T1 - Reduced acquisition time PET pharmacokinetic modelling using simultaneous ASL–MRI

T2 - proof of concept

AU - Scott, Catherine J.

AU - Jiao, Jieqing

AU - Melbourne, Andrew

AU - Burgos, Ninon

AU - Cash, David M.

AU - De Vita, Enrico

AU - Markiewicz, Pawel J.

AU - O'Connor, Antoinette

AU - Thomas, David L.

AU - Weston, Philip S. J.

AU - Schott, Jonathan M.

AU - Hutton, Brian F.

AU - Ourselin, Sebastien

PY - 2019/12

Y1 - 2019/12

N2 - Pharmacokinetic modelling on dynamic positron emission tomography (PET) data is a quantitative technique. However, the long acquisition time is prohibitive for routine clinical use. Instead, the semi-quantitative standardised uptake value ratio (SUVR) from a shorter static acquisition is used, despite its sensitivity to blood flow confounding longitudinal analysis. A method has been proposed to reduce the dynamic acquisition time for quantification by incorporating cerebral blood flow (CBF) information from arterial spin labelling (ASL) magnetic resonance imaging (MRI) into the pharmacokinetic modelling. In this work, we optimise and validate this framework for a study of ageing and preclinical Alzheimer's disease. This methodology adapts the simplified reference tissue model (SRTM) for a reduced acquisition time (RT-SRTM) and is applied to [ 18 F]-florbetapir PET data for amyloid-β quantification. Evaluation shows that the optimised RT-SRTM can achieve amyloid burden estimation from a 30-min PET/MR acquisition which is comparable with the gold standard SRTM applied to 60 min of PET data. Conversely, SUVR showed a significantly higher error and bias, and a statistically significant correlation with tracer delivery due to the influence of blood flow. The optimised RT-SRTM produced amyloid burden estimates which were uncorrelated with tracer delivery indicating its suitability for longitudinal studies.

AB - Pharmacokinetic modelling on dynamic positron emission tomography (PET) data is a quantitative technique. However, the long acquisition time is prohibitive for routine clinical use. Instead, the semi-quantitative standardised uptake value ratio (SUVR) from a shorter static acquisition is used, despite its sensitivity to blood flow confounding longitudinal analysis. A method has been proposed to reduce the dynamic acquisition time for quantification by incorporating cerebral blood flow (CBF) information from arterial spin labelling (ASL) magnetic resonance imaging (MRI) into the pharmacokinetic modelling. In this work, we optimise and validate this framework for a study of ageing and preclinical Alzheimer's disease. This methodology adapts the simplified reference tissue model (SRTM) for a reduced acquisition time (RT-SRTM) and is applied to [ 18 F]-florbetapir PET data for amyloid-β quantification. Evaluation shows that the optimised RT-SRTM can achieve amyloid burden estimation from a 30-min PET/MR acquisition which is comparable with the gold standard SRTM applied to 60 min of PET data. Conversely, SUVR showed a significantly higher error and bias, and a statistically significant correlation with tracer delivery due to the influence of blood flow. The optimised RT-SRTM produced amyloid burden estimates which were uncorrelated with tracer delivery indicating its suitability for longitudinal studies.

KW - arterial spin labelling

KW - cerebral blood flow

KW - pharmacokinetic modelling

KW - Positron emission tomography

KW - reduced acquisition time

UR - https://www.scopus.com/pages/publications/85052082478

U2 - 10.1177/0271678X18797343

DO - 10.1177/0271678X18797343

M3 - Article

C2 - 30182792

SN - 0271-678X

VL - 39

SP - 2419

EP - 2432

JO - Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism

JF - Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism

IS - 12

ER -